Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRadimed Corporation filings document the public-company reporting for a Nasdaq-listed medical-device manufacturer focused on MRI-compatible infusion and patient-monitoring systems. Form 8-K reports furnish quarterly and annual operating results, dividend announcements, guidance updates and other material events tied to the company’s common stock.
Proxy and governance filings describe annual meeting proposals, director elections, auditor ratification, executive compensation, board committee matters and shareholder voting results. Other 8-K disclosures record board composition changes and related committee assignments, providing formal records of governance and capital-structure matters for IRMD.
IRADIMED CORP director Hilda Frederique Scharen-Guivel sold 3,000 shares of Common Stock in open-market transactions at $95.00 per share. The sales occurred on June 4, 2026. Footnotes state that the shares she continues to hold were acquired through the vesting and settlement of restricted stock units granted for her board service.
IRMD submitted a notice under Form 144 reporting a proposed sale of 285,000 shares of Common Stock. The filing lists securities related to RSU vesting (1,766 shares on 10/14/2023 and 1,234 shares on 10/14/2024 and shows 12,783,035 shares outstanding as of 06/04/2026.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open‑market sales of 2,500 shares of Common Stock through the Phillip Susi 2008 Dynasty Trust. The shares were sold on June 1, 2026 in multiple trades at weighted average prices between $88.68 and $91.91, under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 5, 2025.
After these sales, the Phillip Susi 2008 Dynasty Trust held 2,164,600 shares. Separate indirect holdings reported include 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust and 162,950 shares held by the Roger E. Susi Revocable Trust. Susi disclaims beneficial ownership beyond his pecuniary interest in these trust‑held shares.
IRADIMED CORP director and CEO Roger E. Susi reported that the Phillip Susi 2008 Dynasty Trust, an entity associated with him, sold a total of 7,500 shares of common stock in open-market transactions on May 26–27, 2026.
The reported weighted-average sale prices ranged from about $91.85 to $92.93 per share across four trades. After these sales, the trust continued to hold 2,165,333 shares of IRADIMED common stock indirectly. All transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were pre-planned rather than discretionary.
IRADIMED CORP director and CEO Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of Common Stock over May 18–19, 2026. Reported sale prices ranged from about $85.95 to $88.65 per share.
The filing notes these sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted by the reporting person on November 5, 2025, indicating the timing was set in advance. The trust continues to hold a substantial indirect stake in IRADIMED after these transactions, while Susi disclaims beneficial ownership beyond his pecuniary interest.
Iradimed Corporation Amendment No. 3 to a Schedule 13G/A discloses beneficial ownership positions held by Roger E. Susi and related trusts. The filing reports 4,450,450 shares beneficially owned in aggregate, equal to 34.8% of common stock based on April 30, 2026 outstanding shares.
The disclosure breaks ownership into: 162,950 shares held by the Roger E. Susi Revocable Trust, 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, and 2,225,000 shares held by the Phillip Susi 2008 Dynasty Trust. It reports voting and dispositive power allocations and identifies trustees and settlor relationships.
IRADIMED CORP director and CEO Roger E. Susi reported pre-planned insider sales of common stock. Entities associated with him, specifically the Phillip Susi 2008 Dynasty Trust, sold a total of 7,500 shares of IRMD common stock in open-market transactions on May 11 and May 12 under a Rule 10b5-1 trading plan adopted on November 5, 2025. The sales occurred at weighted-average prices around the mid-$80s per share, with execution ranges from $83.11 to $86.00. The filing also records indirect holdings of 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of May 11, reflecting additional indirect ownership structures.
IRADIMED CORP director and CEO Roger E. Susi reported indirect open‑market sales of a total of 7,500 shares of common stock by the Phillip Susi 2008 Dynasty Trust on May 4–5, 2026, at prices including $87.31 and $83.78 per share.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were pre‑scheduled. The filing also reflects indirect holdings through additional family trusts, and Susi disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
IRADIMED CORPORATION delivered solid growth in the first quarter of 2026. Revenue rose to $21.98 million from $19.51 million, driven mainly by stronger sales of MRI-compatible IV infusion pumps and patient monitoring systems, plus higher amortization of extended maintenance agreements.
Net income increased to $5.82 million, or $0.45 per diluted share, compared with $4.69 million, or $0.37 per diluted share, helped by a 77% gross margin and disciplined operating expenses. Cash and cash equivalents grew to $56.37 million, and the company continued returning capital through dividends, with a $0.20 per share quarterly dividend declared for payment in May 2026.
IRADIMED CORPORATION reported strong first-quarter 2026 results, with revenue of $22.0 million, up 13% from $19.5 million a year earlier. GAAP diluted EPS reached $0.45, a 22% increase, and non-GAAP diluted EPS was $0.49, up 17%.
Operating income rose to $7.2 million, up 33%, and gross margin improved to 77%. Cash flow from operations nearly doubled to $8.3 million, driving free cash flow of $7.8 million. The company highlighted the commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, citing strong early demand.
The board declared a regular quarterly cash dividend of $0.20 per share, payable May 29, 2026 to shareholders of record on May 15, 2026. Management issued second-quarter 2026 guidance for revenue of $20.0–$21.0 million and reaffirmed full-year 2026 guidance for revenue of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05.